《CC和CXC趋化因子对HIV-1复制的抑制是遗传亚型非依赖的》

  • 来源专题:艾滋病防治
  • 编译者: 李越
  • 发布时间:2005-04-20
  • We have studied the breadth and potency of the inhibitory actions of the CC chemokines macrophage inhibitory protein 1α (MIP-1α), MIP-1β, and RANTES against macrophage-tropic (M-tropic) primary isolates of human immunodeficiency virus type 1 (HIV-1) and of the CXC chemokine stromal cell-derived factor 1α against T-cell-tropic (T-tropic) isolates, using mitogen-stimulated primary CD4+ T cells as targets. There was considerable interisolate variation in the sensitivity of HIV-1 to chemokine inhibition, which was especially pronounced for the CC chemokines and M-tropic strains. However, this variation was not obviously dependent on the genetic subtype (A through F) of the virus isolates. Peripheral blood mononuclear cell donor-dependent variation in chemokine inhibition potency was also observed. Among the CC chemokines, the rank order for potency (from most to least potent) was RANTES, MIP-1β, MIP-1α. Some M-tropic isolates, unexpectedly, were much more sensitive to RANTES than to MIP-1β, whereas other isolates showed sensitivities comparable to those of these two chemokines. Down-regulation of the CCR5 and CXCR4 receptors occurred in cells treated with the cognate chemokines and probably contributes to anti-HIV-1 activity. Thus, for CCR5, the rank order for down-regulation was also RANTES, MIP-1β, MIP-1α.
  • 原文来源:http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109387
相关报告
  • 《遗传亚型、人体免疫和HIV-1疫苗的发展》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-04-17
    • Successful vaccination programs, particularly against influenza virus infection, have provided us with an awareness of the need to immunize against the predominant circulating viral strains or genetic subtypes. The lessons and language derived from experience with influenza (and a few other) viruses have often been directly translated to human immunodeficiency virus type 1 (HIV-1) vaccine development. But how appropriate is this? Should an HIV-1 vaccine antigen always be based on the dominant genetic subtype that circulates in the geographical area where a vaccine candidate is to be tested? The answers lie, at least in part, in a consideration of the humoral response to HIV-1 and, in particular, in the relationships between the HIV-1 genetic subtypes and antigenic and neutralization serotypes. Here, we will review what is known about these relationships and seek to clarify confusion that has been created by the use of serological assays that generate misleading, or sometimes artifactual, results. Broadly similar issues are raised when considering the relationship between cellular immune responses and the HIV-1 genetic subtypes, but we will not discuss these here. Instead, we refer the reader to recent articles written by leading cellular immunologists . Significantly, a recent study on the cross-clade activity of cytotoxic T-lymphocyte responses in HIV-1-infected Ugandans argued that the use of nonendemic vaccine strains may be initially justified from the perspective of inducing cellular immunity to HIV-1.
  • 《新型小鼠CXC趋化因子受体 申请(专利)号:97182099.6》

    • 来源专题:艾滋病防治
    • 编译者:李越
    • 发布时间:2005-03-16
    • 本发明涉及一种DNA,它编码包括序列表中序列号17记载的全部或部分氨基酸序列的多肽,或包括该多肽的多肽,其中任一种多肽具有能与小鼠PBSF/SDF-1结合的受体活性;由该DNA所编码的、具有能与小鼠PBSF/SDF-1结合的受体活性的多肽;表达该多肽和人CD4蛋白质的细胞;以及以应用该细胞为特征的筛选AIDS发病抑制剂和HIV-1 感染抑制剂的方法。由此本发明提供对研究AIDS的治疗药和HIV-1感染的作用机制有用的、新型小鼠CXC趋化因子受体基因和HIV-1感染抑制剂的筛选方法等。